This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Garlic on Inflammatory Mediators

This study has suspended participant recruitment.
(Results inconclusive)
Information provided by:
Albany Medical College Identifier:
First received: January 10, 2006
Last updated: March 19, 2007
Last verified: March 2007
This research will investigate the effect of garlic oil extract when added to daily diet on inflammatory mediators and blood clotting activation.

Condition Intervention Phase
Healthy Drug: Garlic Oil Macerate Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Garlic Oil Macerate on Inflammatory Mediators in Healthy Normal Weight and Obese Subjects.

Resource links provided by NLM:

Further study details as provided by Albany Medical College:

Primary Outcome Measures:
  • 1. To examine the pharmacokinetics of the garlic oil macerate.

Secondary Outcome Measures:
  • 2. To examine the effect of garlic oil macerate on inflammatory mechanisms at the cellular and molecular level.

Estimated Enrollment: 34
Study Start Date: April 2006
Estimated Study Completion Date: March 2007
Detailed Description:
To investigate the pharmacokinetics of one of the garlic oil macerate, Ajoene, the anti-inflammatory effect of garlic oil macerate on the pro-inflammatory transcription factor NF-kB, it's activating proteins, including IkB, IkB Kinases a and B (IKKa and IKKB) and the pro-inflammatory NF-kB-regulated proteins, c-reactive protein (CRP), tumor necrosis factor-alpha (TNF-a), soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), matrix metalloproteinase-9 (MMP-9), plasminogen activated protein-1 (PAI-1)and the effect of garlic oil macerate intake on platelet activation in normal subjects.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 18 years of age and older
  • Normal subjects with BMI <25, obese subjects with BMI >30
  • Subjects who have consented to adhere to the diet, regular weekly visits, and blood draws.

Exclusion Criteria:

  • Subjects on any antioxidant medication.
  • Patient on non-steroidal anti-inflammatory drug.
  • On any agent with antioxidant properties.
  • History of drug or alcohol abuse.
  • Any life threatening disease.
  • On any agent with significant antioxidant properties.
  • Taking garlic extracts in the diet regularly.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00275405

United States, New York
Albany Medical Center
Albany, New York, United States, 12208
Sponsors and Collaborators
Albany Medical College
Principal Investigator: Howard S Smith, MD Albany Medical College
Principal Investigator: Shaker A Mousa, PhD Albany College of Pharmacy
Principal Investigator: Ahmad Aljada, PhD Albany College of Pharmacy
  More Information Identifier: NCT00275405     History of Changes
Other Study ID Numbers: Ajoene
Study First Received: January 10, 2006
Last Updated: March 19, 2007

Keywords provided by Albany Medical College:
Effects of Garlic

Additional relevant MeSH terms:
Allyl sulfide
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Anticarcinogenic Agents
Antineoplastic Agents
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors processed this record on July 26, 2017